Clinical Insights: Evolving Landscape of Bladder Cancer After GU ASCO 2026

We had the opportunity to dive into the evolving landscape of bladder cancer treatment in this insightful podcast episode at GU ASCO 2026. Featuring expert guests Dr. Chad Reichard, Dr. Shilpa Gupta, Dr. Matt Galsky, and Dr. Sia Daneshmand, the discussion covered the latest FDA-approved options for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), and exciting data that we are seeing presented at GU ASCO 2026.   In this episode, you'll learn about: The current treatment options for MIBC, including neoadjuvant Gem/Cis with perioperative durvalumab vs. EV/pembrolizumab combination Key findings from pivotal studies like KEYNOTE-905, NIAGARA, and KEYNOTE-B15 The implications of these studies on clinical practice and patient management The importance of a multidisciplinary approach in treating bladder cancer Emerging data on BCG plus immunotherapy combinations for NMIBC and their potential impact on treatment protocols Tune in for a comprehensive discussion that highlights the importance of collaboration between medical oncologists and urologists in optimizing patient care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #BladderCancer, #MIBC, #NMIBC, #Immunotherapy, #EVpembro